Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tiragolumab
Tiragolumab and Atezolizumab · 1 trial · 1 indication
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention.
| Arm | Type | Description |
|---|---|---|
| Tiragolumab and Atezolizumab IV FDC | EXPERIMENTAL | Participants will receive tiragolumab and atezolizumab as an intravenous fixed dose combination (IV FDC) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Tiragolumab and Atezolizumab IV FDC | DRUG | Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W). |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy \>=12 weeks * Adequate hematologic and end organ function * Recovery (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia * For fema...
Tiragolumab is an investigational antibody being studied in oncology for several cancers, including esophageal squamous cell carcinoma, small cell lung carcinoma, metastatic breast cancer, triple-negative breast cancer, PD-L1-selected solid tumors, and non-small cell lung cancer (NSCLC). It is in Phase 2 clinical development for these indications.
Tiragolumab is a monoclonal antibody (a -mab class drug) that targets a pathway involved in cancer immunity. It is being studied in combination with other therapies, such as atezolizumab, in clinical trials for various solid tumors.
Tiragolumab is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in multiple cancer types.
Tiragolumab is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or completed to assess its use in various oncology indications.
Tiragolumab has been studied in several trials, including NCT04300647, a Phase 2 study in cervical cancer; NCT04665856, a Phase 3 study in small cell lung cancer; NCT05661578, a Phase 2 study in solid tumors; and NCT06342037, a Phase 2 study in triple-negative breast cancer.
No, Tiragolumab is not the same as atezolizumab. Tiragolumab is a separate investigational antibody that is often studied in combination with atezolizumab, as seen in trials like NCT04300647 and NCT04665856, where the two drugs are given together.